Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

CASC 4.20 +0.09 (2.19%)
price chart
Here's Why Cascadian Therapeutics Inc (USA) (CASC) Shares Tumble 11%
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred stock in concurrent but separate underwritten public offerings.
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that its board of directors has approved a plan for a reverse split of the Company's common stock to increase its share price and reduce the number of authorized and outstanding shares.
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib ...
SEATTLE, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) Likely to Breakout
Investors should take note of the 14% jump in the share price of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) yesterday on a traded volume of 2.01 million shares.
Cowen Dives in on Cascadian Therapeutics Inc (USA) (CASC) Following HER2CLIMB ...
Cowen analyst Boris Peaker weighed in on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) with a few insights after the company announced that following a recent meeting with the FDA and discussions with the Company's external Steering Committee, ...
Abingworth LLP Buys Cascadian Therapeutics Inc, Aurinia Pharmaceuticals Inc ...
London, X0, based Investment company Abingworth LLP buys Cascadian Therapeutics Inc, Aurinia Pharmaceuticals Inc, Immune Design Corp, sells Novan Inc, Dicerna Pharmaceuticals Inc during the 3-months ended 2017-03-31, according to the most ...
Smith Asset Management Group LP Has Upped Target (TGT) Position, Cascadian ...
The SI to Cascadian Therapeutics Incorporated's float is 4.1%. The stock increased 2.19% or $0.09 on May 26, reaching $4.2. About 260,618 shares traded or 43.90% up from the average.
Cascadian Therapeutics Inc (CASC) Announces Earnings Results  Chaffey Breeze
Cascadian Therapeutics: Worth Much More Than The Present Share Price
Despite misgivings about management, the company possesses a promising clinical candidate in tucatinib that is worth much more than the present valuation.
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
EcoR1 Capital, LLC Buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc ...
San Francisco, CA, based Investment company EcoR1 Capital, LLC buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics Inc, Aclaris Therapeutics Inc, OvaScience Inc, Jounce Therapeutics Inc, aTyr Pharma Inc, Atara ...